Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mark Dronsfield, Gregory Lucier

Premium

Personalis, provider of genetic sequencing and data interpretation to researchers and clinicians, this week formed a UK subsidiary and appointed Mark Dronsfield as the director of European sales.

In a statement, Personalis said it plans to build services infrastructure and a European commercial team that will address the exome and genome analysis needs of researchers in overseas markets. Dronsfield was previously the head of commercial operations in Europe for RainDance Technologies and has worked in commercial operations for Illumina, Affymetrix, and Life Technologies.


Sanford-Burnham Medical Research Institute's board of trustees has elected Gregory Lucier as its chairman. Lucier is chairman and CEO of Life Technologies and will take up his post as Sanford-Burnham's board chairman starting September 18.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.